Kezar Life Sciences, Inc. financial data

Symbol
KZR on Nasdaq
Industry
Pharmaceutical Preparations
Location
4000 Shoreline Court, Suite 300, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 998 % -46.4%
Debt-to-equity 19.2 % +47.9%
Return On Equity -59.7 % -65.1%
Return On Assets -50.1 % -56.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 7.3M shares -90%
Common Stock, Shares, Outstanding 7.3M shares -90%
Entity Public Float 173M USD -68.6%
Common Stock, Value, Issued 7K USD -90.4%
Weighted Average Number of Shares Outstanding, Basic 7.3M shares +0.39%
Weighted Average Number of Shares Outstanding, Diluted 7.3M shares +0.39%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 0 USD -100%
Research and Development Expense 72.4M USD -7.14%
General and Administrative Expense 23.6M USD -9.04%
Operating Income (Loss) -104M USD -6.98%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -95.8M USD -9.1%
Earnings Per Share, Basic -0.95 USD/shares +76.7%
Earnings Per Share, Diluted -0.95 USD/shares +76.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 34.9M USD +31.6%
Marketable Securities, Current 114M USD -40.8%
Accounts Receivable, after Allowance for Credit Loss, Current 7M USD
Other Assets, Current 935K USD +14.3%
Assets, Current 156M USD -32.2%
Property, Plant and Equipment, Net 3.15M USD -28.5%
Operating Lease, Right-of-Use Asset 2.14M USD -73.5%
Other Assets, Noncurrent 2.42M USD -61.9%
Assets 164M USD -34.2%
Accounts Payable, Current 3.46M USD +10.9%
Employee-related Liabilities, Current 2.12M USD -27.1%
Accrued Liabilities, Current 9.66M USD -9.32%
Liabilities, Current 20.4M USD +22.5%
Operating Lease, Liability, Noncurrent 3.26M USD -51%
Liabilities 30M USD -9.89%
Accumulated Other Comprehensive Income (Loss), Net of Tax 107K USD
Retained Earnings (Accumulated Deficit) -414M USD -30.1%
Stockholders' Equity Attributable to Parent 134M USD -37.9%
Liabilities and Equity 164M USD -34.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -22.9M USD -9.6%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 20.4M USD +24.5%
Common Stock, Shares Authorized 250M shares 0%
Common Stock, Shares, Issued 7.3M shares -90%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -2.46M USD +43.1%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 34.9M USD +31.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 336K USD +8.39%
Deferred Tax Assets, Valuation Allowance 82.5M USD +44.9%
Deferred Tax Assets, Gross 83.8M USD +41.2%
Operating Lease, Liability 6.65M USD -30.3%
Depreciation 1.2M USD +20%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -95M USD -9.16%
Lessee, Operating Lease, Liability, to be Paid 7.43M USD -34.2%
Property, Plant and Equipment, Gross 9.35M USD -2.02%
Operating Lease, Liability, Current 3.39M USD +17.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.44M USD -13.9%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.99M USD +3.42%
Operating Lease, Weighted Average Discount Rate, Percent 0.12 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 778K USD -55.3%
Lessee, Operating Lease, Liability, to be Paid, Year Three 347K USD -91.5%
Deferred Tax Assets, Operating Loss Carryforwards 43M USD +13.3%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 4.07M USD +61.5%
Lessee, Operating Lease, Liability, to be Paid, Year Four 347K USD +23.1%
Operating Lease, Payments 2.9M USD +42.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 260K USD +0.39%
Deferred Tax Assets, Net of Valuation Allowance 1.28M USD -45.9%
Share-based Payment Arrangement, Expense 12.9M USD -31%
Interest Expense 1.6M USD +6.87%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%